Comparing the Cardiovascular Evidence Both semaglutide and dulaglutide have demonstrated significant cardiovascular benefits in large dedicated outcomes trials, which is a major reason why cardiometabolic guidelines increasingly favour GLP-1 receptor agonists for patients with type 2 diabetes and elevated cardiovascular risk
While increased sweating is not listed as a common side effect of semaglutide in the SmPC, patients taking Ozempic alongside insulin or sulfonylureas should be aware that sweating can be a symptom of hypoglycaemia
Similar to other metabolic diseases, connected devices can gather objective, continuous data in real-world environments and support clinic-based functional assessments for patients participating in weight-loss trials
Well evaluate your health goals, medical history, and lifestyle to recommend the correct type of IV infusion
Decreased appetite (and yes, this is a good thing!) One of the main ways Mounjaro works is by curbing hunger, so feeling less hungry or less likely to snack is part of how the injection aids in weight loss
Combining those with your injection could push you into very high intake territory